Bioresorbable scaffolds are here, please handle with care

Summer 2016 carried exciting news for bioresorbable scaffold (BRS) technology. On July 5, the US Food and Drug Administration (FDA) approved the Absorb GT1 (Abbott Vascular) poly(L-lactide) (PLLA)-based BRS for marketing in the United States. Three weeks earlier on June 15, the CE Mark for marketing in Europe was granted for Magmaris (Biotronik), the first metallic bioresorbable Magnesium-based scaffold. These approvals represent important milestones in the development of coronary BRS technology following nearly two decades of research and development from bench to bed.
Source: Cardiovascular Revascularization Medicine - Category: Cardiology Authors: Tags: Editorial Source Type: research